Biomarkers
tumor, PD‐L1
TUMOR
Out of the 30 patients evaluated, 28 had undergone baseline WES and PD‐L1 expression examination. No significant correlation between pathologic response and baseline tumor mutation burden (TMB) was observed. However, the median TMB in the pCR group was numerically higher than that in the non‐pCR group (3.75 [range: 0.8, 24.8] versus. 2.45 [range: 0.8, 16.4], 